CURSARO, CARMELA
 Distribuzione geografica
Continente #
NA - Nord America 1.004
EU - Europa 281
AS - Asia 228
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 1.517
Nazione #
US - Stati Uniti d'America 1.000
SE - Svezia 101
SG - Singapore 87
IT - Italia 67
CN - Cina 60
HK - Hong Kong 54
GB - Regno Unito 29
DE - Germania 21
ID - Indonesia 18
BG - Bulgaria 11
FR - Francia 8
NL - Olanda 8
FI - Finlandia 7
LT - Lituania 6
RU - Federazione Russa 6
IE - Irlanda 4
CA - Canada 3
ES - Italia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
PK - Pakistan 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BR - Brasile 1
HR - Croazia 1
IN - India 1
JP - Giappone 1
KZ - Kazakistan 1
MX - Messico 1
PE - Perù 1
PT - Portogallo 1
RO - Romania 1
TH - Thailandia 1
Totale 1.517
Città #
Santa Clara 275
Chandler 165
Nyköping 91
Ashburn 81
Fairfield 77
Singapore 75
Hong Kong 53
Houston 31
Seattle 29
Woodbridge 29
Wilmington 23
New York 20
Jakarta 18
Cambridge 16
Princeton 15
Ann Arbor 14
Shanghai 14
London 13
San Diego 11
Sofia 11
Beijing 10
Amsterdam 7
Helsinki 7
Reggio Emilia 7
Moscow 6
Paris 6
Milan 5
Washington 5
Boydton 4
Bremen 4
Buffalo 4
Dublin 4
Modena 4
Munich 4
Secaucus 4
Cavarzere 3
Grafing 3
Kilburn 3
Prescot 3
Augusta 2
Budrio 2
Changchun 2
Chiswick 2
Collecchio 2
Lecce 2
Madrid 2
Mariano Comense 2
Menlo Park 2
Romainville 2
Toronto 2
Wandsworth 2
Xi'an 2
Acton 1
Adnan Menderes 1
Almaty 1
Baveno 1
Bergamo 1
Bologna 1
Boston 1
Brno 1
Castel Maggiore 1
Dallas 1
Delhi 1
Elk Grove Village 1
Guangzhou 1
Istanbul 1
Jacksonville 1
Las Vegas 1
Laval 1
Leipzig 1
Lima 1
Lisbon 1
Los Angeles 1
Nanjing 1
Olomouc 1
Pescara 1
Reggio Nell'emilia 1
Rimini 1
Rome 1
Romola 1
San Mateo 1
Suzhou 1
São Gabriel 1
Tirana 1
Tokyo 1
Turin 1
Tuxtla Gutiérrez 1
Vienna 1
Zagreb 1
Zurich 1
Totale 1.218
Nome #
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 119
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 119
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 86
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 86
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 84
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels 80
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 80
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 79
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 77
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 72
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 71
Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice 70
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance 67
Severe acute respiratory syndrome coronavirus-2-associated cholangiopathies 61
Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment 59
Treatments for hbv: A glimpse into the future 59
Virological Treatment Monitoring for Chronic Hepatitis B 58
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 48
Preliminary results of thymosin-α1 versus IFN-α treatment in patients with HBeAg negative and HBV-DNA positive chronic active hepatitis 44
Indomethacin increases 2′,5′-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis 43
6. A randomized controlled trial of leukocytic IFN-a vs leukocytic IFN-a plus ribavirin in chronic hepatitis C resistant to a previous recombinant or lymphoblastoid IFN treatment 38
Interferon-α plus indomethacin combined therapy in HBeAg positive chronic hepatitis B non-responder to a previous IFNα course: Results of a pilot study 37
Totale 1.537
Categoria #
all - tutte 12.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.832


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021133 0 0 0 0 0 0 16 13 52 2 38 12
2021/2022228 30 16 6 2 4 16 4 34 22 22 36 36
2022/2023442 47 55 45 48 38 56 12 52 68 0 12 9
2023/2024295 11 18 10 39 63 33 20 36 10 7 19 29
2024/2025439 30 6 4 65 205 129 0 0 0 0 0 0
Totale 1.537